

**Minutes of the December 6, 2013  
Pharmacy & Therapeutics (P&T) Committee Meeting  
South Dakota Department of Social Services, Division of Medical Services**

**Members Present**

Mikel Holland, MD; Lenny Petrik, PharmD; Richard Holm, MD; Michelle Baack, MD; Bill Ladwig, RPh; James Engelbrecht, MD

**DSS staff present**

Mike Jockheck, RPh; Ann Schwartz, Dep. Director of Medical Services

**Administrative Business**

The P&T meeting was called to order by B. Ladwig at 1:00pm. The minutes of the September 20, 2013 meeting were presented. M. Baack made a motion to approve. R. Holm seconded the motion. The motion was approved unanimously.

**Prior Authorization Update and Statistics**

The committee reviewed the prior authorization (PA) activity for October 2013. There were a total of 3,554 PA's processed in the month of October, with 99.66% of those requests responded to in less than eight hours. There were 2,679 (75%) requests received electronically and 875 (25%) requests received by fax.

**Analysis of the top 15 Therapeutic Classes**

The committee reviewed the Top 15 Therapeutic Classes by total cost of claims from 7/1/2013 – 9/30/2013. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, central nervous system agents, misc., and corticosteroids (respiratory tract). The top 15 therapeutic classes make up 39.99% of total claims. The Committee also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 10.50% of total claims.

**Quantity Limit Review**

The committee reviewed a list of quantity limit suggestions sorted by Rx count. It was requested that the list be sorted by drug name to remove duplicate entries. An updated list will be reviewed at the next meeting.

**Tramadol Utilization Review**

The committee reviewed tramadol utilization. It was requested that the current PA form be brought to the next meeting for review.

**Hydrocodone Utilization Review**

The committee reviewed hydrocodone utilization and the FDA drug safety communication regarding acetaminophen in prescription drug products. M. Baack made a motion that drug products containing strengths of hydrocodone/acetaminophen other than 5/325 and 10/325 should require a prior authorization. R. Holm seconded the motion. There was no public comment. Motion passed with no audible dissent.

### **Epinephrine Auto-Injection Devices Review**

The committee reviewed utilization data for epinephrine auto-injectors. There was no public comment. This topic was tabled.

### **Brisdelle Review**

The committee reviewed clinical information regarding Brisdelle. J. Engelbrecht made a motion to place Brisdelle on prior authorization. L. Petrick seconded the motion. There was no public comment. The motion passed with no audible dissent. A form will be brought back to the next meeting.

The next meeting is scheduled for March 21, 2014. J. Engelbrecht made a motion to adjourn the P&T Committee meeting. R. Holm seconded the motion. The motion passed unanimously and the meeting was adjourned.